Caris Life Sciences (CAI) Other financing activities (2024 - 2025)
Caris Life Sciences (CAI) recorded quarterly Other financing activities of $5.7 million in Q3 2025, up 192.01% quarter-over-quarter from $1.9 million in Q2 2025, and up 945.2% on a YoY basis from $542000.0 in Q3 2024.
Caris Life Sciences (CAI) Other financing activities (2024 - 2025) Analysis & Trends
Caris Life Sciences' Other financing activities history runs 2 years deep, the most recent figure standing at $5.7 million for Q3 2025.
- In Q3 2025, Other financing activities rose 945.2% year-over-year to $5.7 million; the TTM figure through Mar 2026 stood at $7.6 million (changed N/A YoY), while the FY2025 annual figure was $7.7 million, up 628.05% from the prior year.
- Other financing activities was $5.7 million for Q3 2025 at Caris Life Sciences, up from $1.9 million in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $5.7 million in Q3 2025 to a low of $25000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Caris Life Sciences | 5.22 Bn | 4.40 Bn | 171.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 5.67 Mn |
| Sep 30, 2025 | 5.67 Mn |
| Jun 30, 2025 | 1.94 Mn |
| Jun 30, 2025 | 1.94 Mn |
| Mar 31, 2025 | 105,000.00 |
| Mar 31, 2025 | 105,000.00 |
| Dec 31, 2024 | 25,000.00 |
| Dec 31, 2024 | 25,000.00 |
| Sep 30, 2024 | 542,000.00 |
| Sep 30, 2024 | 542,000.00 |